Nuevocor

Nuevocor is a biotechnology company based in Singapore, founded in 2020.

It specializes in developing genetic medicines aimed at treating untreatable cardiomyopathies, which are aggressive heart muscle diseases. The company employs a mechanobiology-centered approach that targets the underlying mechanical defects of these conditions, rather than just individual gene mutations. Nuevocor has received FDA clearance for its lead candidate, NVC-001, an AAV-based gene therapy designed to address LMNA-related dilated cardiomyopathy, a severe genetic heart condition. The company has raised $80.6 million in funding, including a $24 million Series A and a $45 million Series B round, to support its clinical development efforts. With a team of approximately 29 employees, Nuevocor is expanding its operations into Europe and serves the healthcare sector, focusing on patients with genetic heart conditions that currently lack effective treatments.